Diclofenac Potassium.

  An HPTLC method for simultaneous determination of Camylofin Dihydrochloride and Diclofenac Potassium in a pharmaceutical formulation has been developed and validated. The analyte were separated on silica gel 60F254 HPTLC plates with Benzene: Methanol: Ammonia in the ratio of 8.0:2.0:0.2, as mobile phase, after chamber saturation for 15 min. The development distance was 9 cm. The plate was then dried in air and scanned and quantified at the wavelength at 220 nm. The limits of detection were 25 μg mL–1 and 30 μg mL–1 for Camylofin Dihydrochloride and Diclofenac Potassium respectively. The limits of quantification were 50 μg mL–1 and 60 μg mL–1 for Camylofin Dihydrochloride and Diclofenac Potassium respectively. The method enables accurate, precise, and rapid simultaneous analysis of Camylofin Dihydrochloride and Diclofenac Potassium. It can be conveniently adopted for routine quality control analysis. Key words: HPTLC, Camylofin Dihydrochloride, Diclofenac Potassium.